MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
3. Government_Funders & Regulators
*Government: International
Europe
*Europe: Regions
*Western Europe
Ireland
*Industry: Ireland
Prothena Corporation plc (NASDAQ:PRTA)*
Organization & Developments: Prothena
Parents
Prothena Corporation plc (NASDAQ:PRTA)*
Children
*Neurodegenerative diseases
2018: An Investment Play On Prothena - Bret Jensen
2018: Prothena shares surge on Celgene collaboration
2018: Prothena Still Remains A Great Short Opportunity After Workforce Reduction - Prothena Corp plc (NASDAQ:PRTA)
2018: Prothena: What's Left?_seekingalpha.com
2018: PRTA -69% late-stage fail; EPZM clinical hold • BioPharmCatalyst
2020: Unfazed by PhII miss, Roche ushers Prothena's Parkinson's drug into late-stage trial
2022: Prothena: Paying A Premium To Cover All The Alzheimer's Bases_ seekingalpha.com
2023: Prothena: Upcoming Alzheimer's Data Could Solidify Its Position In The Market_seekingalpha.com
2024: Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment_MSN
2024: Prothena Corporation plc 2023 Q4 - Results - Earnings Call Presentation
2024: Prothena Surges After Parkinson's Drug Misses Primary Endpoint
2024: Prothena: Alzheimer's Data Update In 2024 Could Move The Needle
2024: Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade)
2024: Prothena’s Parkinson’s study fails primary endpoint despite some success
2025: Can Prothena's $472M War Chest and Multiple 2025 Trial Results Transform Its Market Position?
2025: Prothena Corporation: Multiple Failures Make It Risky
2025: Prothena to evaluate options after phase 3 birtamimab failure; shares plunge
2025: Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place
2025: Prothena's SWOT analysis: neurodegenerative disease pipeline drives stock potential By Investing.com
Jumps
*Key People: Prothena
Finance & Acquisitions: Prothena